Comparison of the efficacy and safety of two different lasers in the treatment of melasma

Comparison of the efficacy and safety of Low-Fluence Q-Switched 1,064 nm Nd:YAG Laser and Low-Fluence CO2 Fractional Laser for treatment of melasma in patients referred to Shohada-e Tajrish hospital during 2012 :A Randomized Controlled Split-Face Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201201318146N2

Enrollment

Registered

2012-08-27

Start date

2012-08-12

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma. Chloasma

Interventions

Intervention 1: Each side of face is being numbed by cream lidocain 30 minutes before starting the procedure. In one side of the face, Q-Switched ND:YAG 1,064 laser with 1.5-2 j/cm2 fluence and 7 mi

Treatment - Other

Each side of face is being numbed by cream lidocain 30 minutes before starting the procedure. In one side of the face, Q-Switched ND:YAG 1,064 laser with 1.5-2 j/cm2 fluence and 7 mili meter spot s

In the other side, the Low-Power Fractional CO2 laser with 1 j enery and 0.7 density is being used.

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: All patients suffering from melasma that referred for treatment in during 2012 to the shohada-e tajrish treatment center form the study population. Study inclusion criteria: -Age between 18 to 85 years old - Fitzpatrick skin type I-V - symmetric distribution of melasma the in both sides of patient's face study exclusion criteria: -usage of pigment reducing topical treatments 2 weeks prior to the study -usage of peeling agents 2 weeks prior to the study -laser therapy for melasma 1 month prior to the study -a history of poor wound healing, or abnormal scarring -pregnancy or breast feeding -history of keloid -high exposure to sunlight or UV light 1 month prior to the study -concurrent active herpes simplex lesion of the skin -suspected hypersensitivity to lidocaine -bleeding disorders

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Melanin Index. Timepoint: After laser therapy. Method of measurement: Multi Probe adaptor.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNiloofar Jalali

Laser aplication in medical sciences research center

niloofar.jalaly@yahoo.fr+98 21 2274 9221

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026